论文部分内容阅读
目的 了解乳腺浸润性导管癌中雌激素调节蛋白 (PS2 )和谷胱甘肽S 转移酶π(GSTπ)的表达及其对预后和治疗的指导作用。方法 用标记的链亲和素生物素 (LSAB)免疫组化法对 2 10例乳腺浸润性导管癌患者的石蜡标本进行PS2和GSTπ的检测。结果 PS2的表达阳性率为 4 9.5 % ,GSTπ的表达阳性率为 4 8.1%。术后 5年和 10年生存率从高到低依次为PS2表达阳性 /GSTπ表达阴性组、PS2表达阳性 /GSTπ表达阳性组、PS2表达阴性 /GSTπ表达阴性组和PS2表达阴性 /GSTπ表达阳性组。结论 PS2表达阳性 /GSTπ表达阴性组患者的预后最好 ,PS2表达阳性 /GSTπ表达阳性组和PS2表达阴性 /GSTπ表达阳性组患者的预后次之 ,PS2表达阴性 /GSTπ表达阳性组患者的预后最差。因此 ,在临床中应根据患者的情况合理应用内分泌治疗和化疗。
Objective To investigate the expression of estrogen-regulated protein (PS2) and glutathione S-transferase π (GSTπ) in invasive ductal carcinoma of the breast and its guiding effect on prognosis and treatment. METHODS: Paraffin-embedded specimens of 20 invasive ductal breast cancer patients were examined for PS2 and GSTπ using labeled streptavidin biotinylated (LSAB) immunohistochemistry. Results The positive rate of PS2 was 49.5 %, and the positive rate of GSTπ was 4 8.1 %. The 5-year and 10-year survival rates from high to low were PS2 positive/GSTπ negative, PS2 positive/GSTπ positive, PS2 negative/GSTπ negative and PS2 negative/GSTπ positive. . Conclusion The patients with PS2 positive expression/GSTπ negative expression group had the best prognosis. The patients with PS2 positive expression/GSTπ positive expression group and PS2 negative expression/GSTπ positive expression group had the second best prognosis. PS2 negative expression/GSTπ positive expression group had the best prognosis difference. Therefore, in the clinic, endocrine therapy and chemotherapy should be reasonably applied according to the patient’s condition.